BofA analyst Travis Steed initiated coverage of Carlsmed (CARL) with a Buy rating and $16 price target The firm says the company’s Aprevo platform is ushering in a new standard of care in spine fusion surgery with custom 3D printed interbody implants. BofA’s views its forecast of Carlsmed adding 20-25 new surgeons each quarter through 2027 as conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL: